Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gain Therapeutics, Inc. - Common Stock
(NQ:
GANX
)
1.860
+0.060 (+3.34%)
Streaming Delayed Price
Updated: 3:14 PM EDT, Apr 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gain Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
November 14, 2023
Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
These Apple Insiders Are Selling Shares of AAPL Stock
↗
October 04, 2023
Apple stock is on the move Wednesday after several insiders at the company, including CEO Tim Cook, sold shares of AAPL.
Via
InvestorPlace
Why Is Nvni Group (NVNI) Stock Down 8% Today?
↗
October 04, 2023
Nvni Group is seeing shares of NVNI stock fall on Wednesday following the company's debut debut yesterday following a SPAC merger.
Via
InvestorPlace
Why Is Gain Therapeutics (GANX) Stock Moving Today?
↗
October 04, 2023
Gain Therapeutics stock is on the move Wednesday as investors in GANX react to updated clinical trial news from the company.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
October 04, 2023
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday.
Via
InvestorPlace
Expert Ratings for Gain Therapeutics
↗
June 12, 2023
Via
Benzinga
Chardan Capital Maintains Buy Rating for Gain Therapeutics: Here's What You Need To Know
↗
May 15, 2023
Via
Benzinga
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
October 04, 2023
First small molecule allosteric binder discovered with Gain’s computational drug discovery platform enters clinical development
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
September 25, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference
September 20, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Where Gain Therapeutics Stands With Analysts
↗
May 15, 2023
Via
Benzinga
Analyst Expectations for Gain Therapeutics's Future
↗
May 15, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
↗
September 12, 2023
Via
Benzinga
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
September 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
August 29, 2023
Via
Get News
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
August 29, 2023
--News Direct--
Via
News Direct
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
August 29, 2023
Bethesda, MD, August 29, 2023 (PlatoData via 500NewsWire) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies,...
Via
TheNewswire.com
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
August 28, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
August 10, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
August 07, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference
July 31, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
May 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease
May 03, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
April 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
March 29, 2023
Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer’s disease
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
March 23, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
March 22, 2023
Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm ET
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
March 21, 2023
Grant awarded to consortium led by Gain Therapeutics to advance the development of proprietary allosteric small molecule regulators against Alpha-1 Antitrypsin (AAT) Deficiency
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 09, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
